Gender differences in the regulation of vascular tone

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 1-2, 2003, Pages 1-15

  Thompson, Janell ^a   Khalil, Raouf A ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coronary artery disease; Endothelium; Hypertension; Sex hormones; Signal transduction; Vascular smooth muscle

Indexed keywords

CALCIUM; CYCLIC AMP; CYCLIC GMP; ESTROGEN; ESTROGEN RECEPTOR; NITRIC OXIDE; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTACYCLIN; PROTEIN KINASE C; SEX HORMONE; TESTOSTERONE;

BLOOD VESSEL TONE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOSOL; FEMALE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERPOLARIZATION; HYPERTENSION; MALE; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; SEX DIFFERENCE; SHORT SURVEY; SMOOTH MUSCLE CONTRACTION; VASODILATATION;

ENDOTHELIUM, VASCULAR; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPERTENSION; MALE; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; SEX CHARACTERISTICS; VASODILATION;

EID: 0037283217     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03790.x     Document Type: Short Survey

References (163)

1. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 1995; 92: 5-8.
2. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996; 10: 615-24.
3. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-7.
4. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year followup from the Nurses's Health Study. N. Engl. J. Med. 1991; 325: 756-62.
5. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342: 133-6.
6. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 1996; 335: 453-61.
7. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995; 25: 305-13.
8. August P, Oparil S. Hypertension in women. J. Clin. Endocrinol. Metab. 1999; 84: 1862-6.
9. Mercuro G, Zoncu S, Piano D et al. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am. J. Hypertens. 1998; 11: 909-13.
10. Chasan-Taber L, Willett WC, Manson JE et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483-9.
11. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-18.
12. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33: 1190-4.
13. Scuteri A, Bos AJ, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann. Intern. Med. 2001; 135: 229-38.
14. Lip GY, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J. Hum. Hypertens. 1994; 8: 491-4.
15. Oparil S. Hypertension in postmenopausal women: Pathophysiology and management. Curr. Opin. Nephrol. Hypertens. 1995; 4: 438-42.
16. Rosano GM, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J. Am. Coll. Cardiol. 2000; 36: 2154-9.
17. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996; 94: 2221-7.
18. Hinojosa-Laborde C, Lange DL, Haywood JR. Role of female sex hormones in the development and reversal of Dahl hypertension. Hypertension 2000; 35: 484-9.
19. Rowland NE, Fregly MJ. Role of gonadal hormones in hypertension in the Dahl salt-sensitive rat. Clin. Exp. Hypertens. 1992; A14: 367-75.
20. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199-208.
21. Bayorh MA, Socci RR, Eatman D, Wang M, Thierry-Palmer M. The role of gender in salt-induced hypertension. Clin. Exp. Hypertens. 2001; 23: 241-55.
22. Sasaki T, Ohno Y, Otsuka K, Suzawa T, Suzuki H, Saruta T. Oestrogen attenuates the increases in blood pressure and platelet aggregation in ovariectomized and salt-loaded Dahl salt-sensitive rats. J. Hypertens. 2000; 18: 911-17.
23. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension 1997; 29: 494-9.
24. David FL, Carvalho MH, Cobra AL et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38: 692-6.
25. Packer CS, Pelaez NJ, Kramer JA. Estrogen protects against hypertension in the spontaneously hypertensive rat, but its protective mechanism is unrelated to impaired arterial muscle relaxation. J. Gender Specific Med. 2001; 4: 20-7.
26. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2004-9.
27. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19: 456-63.
28. Simon JA, Hsia J, Cauley JA et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103: 638-42.
29. Cox DA, Cohen ML. Influence of gender on vasomotor effects of oxidized low-density lipoprotein in porcine coronary arteries. Am. J. Physiol. 1997; 272: H2577-83.
30. Rosano GM, Leonardo F, Pagnotta P et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-70.
31. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur. Heart J. 2000; 21: 890-4.
32. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-6.
33. Slowinska-Srzednicka J, Malczewska B, Srzednicki M et al. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J. Intern. Med. 1995; 237: 465-72.
34. 4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1996; 19: 1045-50.
35. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism 1992; 41: 1110-14.
36. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051-7.
37. van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 1998; 30: 27-36.
38. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet. Gynecol. 1993; 81: 261-4.
39. Beldekas JC, Smith B, Gerstenfeld LC, Sonenshein GE, Franzblau C. Effects of 17beta-estradiol on the biosynthesis of collagen in cultured bovine aortic smooth muscle cells. Biochemistry 1981; 20: 2162-7.
40. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999; 33: 177-82.
41. + channels. Circ. Res. 1996; 79: 1024-30.
42. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97: 1234-8.
43. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 1034-40.
44. Mercuro G, Pitzalis L, Podda A et al. Effects of acute administration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women. Am. J. Cardiol. 1999; 84: 214-18.
45. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am. J. Physiol. 1991; 261: R1022-7.
46. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154-60.
47. i during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J. Pharmacol. Exp. Ther. 1999; 291: 44-52.
48. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation 1999; 99: 2688-93.
49. Kim-Schulze S, McGowan KA, Hubchak SC et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996; 94: 1402-7.
50. Harder DR, Coulson PB. Estrogen receptors and effects on membrane electrical properties of coronary vascular smooth muscle. J. Cell Physiol. 1979; 100: 375-82.
51. McGill Jr HC, Sheridan PJ. Nuclear uptake of sex steroid hormones in the cardiovascular system of the baboon. Circ. Res. 1981; 48: 238-44.
52. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J. Clin. Invest. 1982; 69: 750-8.
53. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89: 1501-10.
54. 2+ uptake. Circ. Res. 1997; 81: 242-8.
55. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J. Steroid Biochem. Mol. Biol. 1998; 64: 187-91.
56. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994; 89: 1943-450.
57. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: Prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation 2000; 101: 1792-8.
58. Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA, Mendelsohn ME. Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ. Res. 1998; 83: 224-9.
59. Ingegno MD, Money SR, Thelmo W et al. Progesterone receptors in the human heart and great vessels. Lab. Invest. 1988; 59: 353-6.
60. Sheridan PJ, McGill Jr HC. The nuclear uptake and retention of a synthetic progestin in the cardiovascular system of the baboon. Endocrinology 1984; 114: 2015-19.
61. Vazquez F, Rodriguez-Manzaneque JC, Lydon JP, Edwards DP, O'Malley BW, Iruela-Arispe ML. Progesterone regulates proliferation of endothelial cells. J. Biol. Chem. 1999; 274: 2185-92.
62. Tamaya T, Wada K, Nakagawa M et al. Sexual dimorphism of binding sites of testosterone and dihydrotestosterone in rabbit model. Comp. Biochem. Physiol. 1993; 105A: 745-9.
63. 2 receptors in rat aortic smooth-muscle cells. J. Cardiovasc. Pharmacol. 1997; 29: 311-15.
64. Landers JP, Spelsberg TC. New concepts in steroid hormone action: Transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit. Rev. Eukaryot. Gene Expr. 1992; 2: 19-63.
65. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, Ritter JM. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J. Am. Coll. Cardiol. 2000; 36: 1233-8.
66. Higashi Y, Sanada M, Sasaki S et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001; 37: 651-7.
67. Magness RR, Rosenfeld CR. Local and systemic estradiol 17β: Effects on uterine and systemic vasodilation. Am. J. Physiol. 1989; 256: E536-42.
68. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon 3rd RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786-91.
69. Hermsmeyer K, Miyagawa K, Kelley ST et al. Reactivity-based coronary vasospasm independent of atherosclerosis in Rhesus monkeys. J. Am. Coll. Cardiol. 1997; 29: 671-80.
70. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-estradiol in vitro. Br. J. Pharmacol. 1991; 104: 1033-7.
71. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17beta-oestradiol in vitro. Cardiovasc. Res. 1993; 27: 1939-42.
72. Ca channels through a cGMP-dependent mechanism. Circ. Res. 1995; 77: 936-42.
73. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17beta-estradiol on endothelium-dependent responses in the rabbit. J. Pharmacol. Exp. Ther. 1988; 244: 19-22.
74. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am. J. Cardiol. 1994; 73: 951-2.
75. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17beta-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am. J. Physiol. 1992; 263: H271-5.
76. 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin. Exp. Pharmacol. Physiol. 1999; 26: 707-15.
77. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm. Metab. Res. 2001; 33: 645-52.
78. Garcia-Villalon AL, Buchholz JN, Krause DN, Duckles SP. Sex differences in the effects of 17beta-estradiol on vascular adrenergic responses. Eur. J. Pharmacol. 1996; 314: 339-45.
79. Shaw L, Taggart M, Austin C. Effects of the oestrous cycle and gender on acute vasodilatory responses of isolated pressurized rat mesenteric arteries to 17beta-oestradiol. Br. J. Pharmacol. 2001; 132: 1055-62.
80. Kakucs R, Varbiro S, Nadasy GL, Monos E, Szekacs B. Acute, nongenomic vasodilatory action of estradiol is attenuated by chronic estradiol treatment. Exp. Biol. Med. 2001; 226: 538-42.
81. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J. Appl. Physiol. 2002; 92: 701-8.
82. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur. J. Pharmacol. 1992; 211: 163-7.
83. Hutchison SJ, Sudhir K, Chou TM et al. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. J. Am. Coll. Cardiol. 1997; 29: 800-7.
84. Greenberg S, Geroge WR, Kadowitz PJ, Wilson WR. Androgen-induced enhancement of vascular reactivity. Can. J. Physiol. Pharmacol. 1974; 52: 14-22.
85. Quan A, Teoh H, Man RY. Acute exposure to a low level of testosterone impairs relaxation in porcine coronary arteries. Clin. Exp. Pharmacol. Physiol. 1999; 26: 830-2.
86. 2 mimetic induced coronary artery vasoconstriction in guinea pigs. Eur. J. Clin. Invest. 1994; 24 (Suppl. 1): 50-2.
87. Chou TM, Sudhir K, Hutchinson SJ et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 1996; 94: 2614-19.
88. Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J. Pharmacol. Exp. Ther. 1996; 277: 34-9.
89. Kauser K, Rubanyi GM. Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 1995; 25: 517-23.
90. Lieberman EH, Gerhard MD, Uehata A et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 1994; 121: 936-41.
91. Kahonen M, Tolvanen JP, Sallinen K, Wu X, Porsti I. Influence of gender on control of arterial tone in experimental hypertension. Am. J. Physiol. 1998; 275: H15-22.
92. Molinari C, Battaglia A, Grossini E et al. The effect of progesterone on coronary blood flow in anaesthesized pigs. Exp. Physiol. 2001; 86: 101-8.
93. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman Y, Knoll E, Stern N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 1998; 32: 39-45.
94. Kauser K, Rubanyi GM. Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae. Am. J. Physiol. 1994; 267: H2311-17.
95. 2+ and ecNOS activity. Am. J. Physiol. 1999; 276: H961-9.
96. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am. J. Physiol. 1997; 272: H2765-73.
97. Meyer MC, Cummings K, Osol G. Estrogen replacement attenuates resistance artery adrenergic sensitivity via endothelial vasodilators. Am. J. Physiol. 1997; 272: H2264-70.
98. Geary GG, Krause DN, Duckies SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H511-19.
99. Thompson LP, Pinkas G, Weiner CP. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 2000; 102: 445-51.
100. x release in human coronary artery endothelium. J. Cardiovasc. Pharmacol. 2000; 36: 242-7.
101. Kauser K, Rubanyi GM. Potential cellular signaling mechanisms mediating upregulation of endothelial nitric oxide production by estrogen. J. Vasc. Res. 1997; 34: 229-36.
102. Tan E, Gurjar MV, Sharma RV, Bhalla RC. Estrogen receptor-alpha gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration. Cardiovasc. Res. 1999; 43: 788-97.
103. MacRitchie AN, Jun SS, Chen Z et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ. Res. 1997; 81: 355-62.
104. Sumi D, Hayashi T, Jayachandran M, Iguchi A. Estrogen prevents destabilization of endothelial nitric oxide synthase mRNA induced by tumor necrosis factor alpha through estrogen receptor mediated system. Life Sci. 2001; 69: 1651-60.
105. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl Acad. Sci. USA 2000; 97: 5930-5.
106. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 1999; 96: 2788-93.
107. 2+ concentration in rat valvular endothelial cells. Biochem. Biophys. Res. Commun. 1998; 248: 916-19.
108. Rubio-Gayosso I, Sierra-Ramirez A, Garcia-Vazquez A et al. 17Beta-estradiol increases intracellular calcium concentration through a short-term and nongenomic mechanism in rat vascular endothelium in culture. J. Cardiovasc. Pharmacol. 2000; 36: 196-202.
109. 2+ mobilization. Circ. Res. 1997; 81: 885-92.
110. Hisamoto K, Ohmichi M, Kurachi H et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 2001; 276: 3459-67.
111. Hernandez I, Delgado JL, Diaz J et al. 17Beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 279: R1599-605.
112. Wassmann S, Baumer AT, Strehlow K et al. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 2001; 103: 435-41.
113. Wagner AH, Schroeter MR, Hecker M. 17Beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J. 2001; 15: 2121-30.
114. Barbacanne MA, Rami J, Michel JB et al. Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: Possible role of decreased endothelium-derived superoxide anion production. Cardiovasc. Res. 1999; 41: 672-81.
115. Rosenfeld CR, White RE, Roy T, Cox BE. Calcium-activated potassium channels and nitric oxide coregulate estrogen-induced vasodilation. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H319-28.
116. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am. J. Physiol. Heart Circ. Physiol. 2001; 280: H1699-705.
117. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H1720-7.
118. Barber DA, Miller VM. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am. J. Physiol. 1997; 273: H2325-32.
119. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J. Clin. Invest. 1998; 102: 176-83.
120. Sakuma I, Liu MY, Sato A et al. Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: Influence of oestrogen. Br. J. Pharmacol. 2002; 135: 48-54.
121. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M. Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br. J. Pharmacol. 2001; 132: 1035-46.
122. Honda H, Unemoto T, Kogo H. Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 1999; 34: 1232-6.
123. Tostes RC, David FL, Carvalho MH, Nigro D, Scivoletto R, Fortes ZB. Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. J. Cardiovasc. Pharmacol. 2000; 36 (Suppl. 1): S99-101.
124. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001; 37: 640-4.
125. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, Levin ER. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem. J. 1998; 330: 1097-105.
126. Bilsel AS, Moini H, Tetik E, Aksungar F, Kaynak B, Ozer A. 17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc. Res. 2000; 46: 579-84.
127. Webb CM, Ghatei MA, McNeill JG, Collins P. 17Beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 2000; 102: 1617-22.
128. Bacakova L, Kunes J. Gender differences in growth of vascular smooth muscle cells isolated from hypertensive and normotensive rats. Clin. Exp. Hypertens. 2000; 22: 33-44.
129. Suzuki A, Mizuno K, Ino Y et al. Effects of 17beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovasc. Res. 1996; 32: 516-23.
130. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am. J. Physiol. 1997; 272: H1996-2003.
131. Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996; 93: 577-84.
132. Dai-Do D, Espinosa E, Liu G et al. 17Beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: Similar effects in cells from postmenopausal females and in males. Cardiovasc. Res. 1996; 32: 980-5.
133. Morey AK, Pedram A, Razandi M et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997; 138: 3330-9.
134. Takeda-Matsubara Y, Nakagami H, Iwai M et al. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension 2002; 39: 41-5.
135. Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat. Med. 1997; 3: 1005-8.
136. Stallone JN, Crofton JT, Share L. Sexual dimorphism in vasopressin-induced contraction of rat aorta. Am. J. Physiol. 1991; 260: 14453-8.
137. 2+ entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 1999; 34: 931-6.
138. Crofton JT, Ratliff DL, Brooks DP, Share L. The metabolic clearance rate of and pressor responses to vasopressin in male and female rats. Endocrinology 1986; 118: 1777-81.
139. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am. J. Physiol. Cell Physiol. 2001; 280: C34-C45.
140. Herkert O, Kuhl H, Busse R, Schini-Kerth VB. The progestin levonorgestrel induces endothelium-independent relaxation of rabbit jugular vein via inhibition of calcium entry and protein kinase C. Role of cyclic AMP. Br. J. Pharmacol. 2000; 130: 1911-18.
141. Collins P, Rosano GM, Sarrel PM et al. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24-30.
142. Nickenig G, Strehlow K, Wassmann S et al. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation 2000; 102: 1828-33.
143. Minshall RD, Pavcnik D, Halushka PV, Hermsmeyer K. Progesterone regulation of vascular thromboxane A(2) receptors in Rhesus monkeys. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H1498-507.
144. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. Physiol. Rev. 1996; 76: 967-1003.
145. Khalil RA, van Breemen C. Mechanisms of calcium mobilization and homeostasis in vascular smooth muscle and their relevance to hypertension. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, New York. 1995; 523-40.
146. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 2000; 522: 177-85.
147. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-14.
148. Kanashiro CA, Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin. Exp. Pharmacol. Physiol. 1998; 25: 974-85.
149. i in vascular smooth muscle cells of female rat. Am. J. Physiol. Cell Physiol. 2000; 278: C834-44.
150. 2+ currents in A7r5 vascular smooth muscle cell line. Am. J. Physiol. 1994; 266: C975-80.
151. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J. Gen. Physiol. 1997; 110: 135-40.
152. 2+ current and adaptation to exercise training in miniature swine. J. Appl. Physiol. 2001; 91: 2503-10.
153. Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen: A calcium antagonist effect? Lancet 1993; 341: 1264-5.
154. 2 in porcine coronary artery. Circulation 1995; 91: 2619-26.
155. Kitazawa T, Hamada E, Kitazawa K, Gaznabi AK. Non-genomic mechanism of 17beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J. Physiol. 1997; 499: 497-511.
156. 2+ currents in aortic smooth muscle. Eur. J. Pharmacol. 1995; 294: 625-35.
157. 2+ efflux from female porcine coronary arterial smooth muscle. Am. J. Physiol. 1999; 276: 14926-34.
158. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17Beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim. Biophys. Acta 1998; 1406: 169-74.
159. Nilsson BO, Ekblad E, Heine T, Gustafsson JA. Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knockout mice. J. Endocrinol. 2000; 166: R5-9.
160. Zhu Y, Bian Z, Lu P et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002; 295: 505-8.
161. Szekacs B, Vajo Z, Acs N et al. Hormone replacement therapy reduces mean 24 hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000; 7: 31-5.
162. Hsia J, Simon JA, Lin F et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease. The Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102: 2228-32.
163. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 2000; 343: 522-9.